We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Antibody-Drug Conjugate Shows Promising Activity in Advanced or Metastatic EGFR Mutation-Positive NSCLC.
- Authors
Stewart, Patricia
- Abstract
The article reports that Patritumab deruxtecan (HER3- DxD), an investigational antibody–drug conjugate targeting the HER3 growth factor receptor, showed promising activity in patients with locally advanced or metastatic EGFR mutation–positive non–small-cell lung cancer (NSCLC) who had received previous EGFR tyrosine kinase inhibitor (TKI) therapy. It mentions that EGFR tyrosine kinase inhibitor resistance is often difficult to treat and has diverse resistance mechanisms.
- Subjects
ANTIBODY-drug conjugates; EPIDERMAL growth factor receptors
- Publication
Oncology Practice Management, 2021, Vol 11, Issue 12, p28
- ISSN
2164-4403
- Publication type
Article